PURE Bioscience (PURE, Financial) filed Quarterly Report for the period ended 2011-01-31.
Pure Bioscience has a market cap of $62.9 million; its shares were traded at around $1.7 with and P/S ratio of 44.5. Pure Bioscience had an annual average earning growth of 4.7% over the past 5 years.
Our net loss after income taxes increased by $1,023,200, from a net loss of $3,477,400, or $0.10 per share, for the six months ended January 31, 2010 to a net loss of $4,500,600, or $0.12 per share, for the Six Months.
At January 31, 2011, we had cash and cash equivalents of $1,677,800, a decline of $514,800 from July 31, 2010. Net cash used in operations, and for investments in both intangible and fixed assets, was $3,336,000 in the Six Months, $5,853,500 in Fiscal 2010, and $6,107,400 for the fiscal year ended July 31, 2009 (“Fiscal 2009”). At January 31, 2011, we had no short-term investments and no long-term debt. Total current assets at January 31, 2011 were $3,007,300, a decline of $416,400 from July 31, 2010.
During the Six Months, cash used in investing activities was $151,200, consisting primarily of investments in patents. At January 31, 2011, the net book value of our capitalized patents was $1,923,000, and the net book value of our property, plant and equipment was $563,700. In the six month period ended January 31, 2010, cash used in investing activities was $260,900, consisting of investments in patents of $68,200 and purchases of property, plant and equipment of $192,700.
Also during the Six Months, we received $259,100 from the exercise of warrants to purchase 123,365 shares of our common stock, at an average exercise price of $2.10 per share, and we received $195,100 from the exercise of 335,000 common stock options, at an average exercise price of $0.58 per share.
At January 31, 2011, we had total liabilities of $1,173,900, an increase of $574,700 from July 31, 2010. Included in current liabilities is $322,100 of deferred revenue related to amounts billed for product shipped where payment on agreed terms was not reasonably assured at the time of shipment. Accounts payable and accrued liabilities also increased from July 31, 2010, by $268,700, due primarily to the timing of accounts payable and accrued salaries and wages.
Read the The complete Report
Pure Bioscience has a market cap of $62.9 million; its shares were traded at around $1.7 with and P/S ratio of 44.5. Pure Bioscience had an annual average earning growth of 4.7% over the past 5 years.
Highlight of Business Operations:
Our net loss after income taxes increased by $713,400, from a net loss of $1,766,200, or $0.05 per share, for the three months ended January 31, 2010 to a net loss of $2,479,600, or $0.07 per share, for the Second Quarter.Our net loss after income taxes increased by $1,023,200, from a net loss of $3,477,400, or $0.10 per share, for the six months ended January 31, 2010 to a net loss of $4,500,600, or $0.12 per share, for the Six Months.
At January 31, 2011, we had cash and cash equivalents of $1,677,800, a decline of $514,800 from July 31, 2010. Net cash used in operations, and for investments in both intangible and fixed assets, was $3,336,000 in the Six Months, $5,853,500 in Fiscal 2010, and $6,107,400 for the fiscal year ended July 31, 2009 (“Fiscal 2009”). At January 31, 2011, we had no short-term investments and no long-term debt. Total current assets at January 31, 2011 were $3,007,300, a decline of $416,400 from July 31, 2010.
During the Six Months, cash used in investing activities was $151,200, consisting primarily of investments in patents. At January 31, 2011, the net book value of our capitalized patents was $1,923,000, and the net book value of our property, plant and equipment was $563,700. In the six month period ended January 31, 2010, cash used in investing activities was $260,900, consisting of investments in patents of $68,200 and purchases of property, plant and equipment of $192,700.
Also during the Six Months, we received $259,100 from the exercise of warrants to purchase 123,365 shares of our common stock, at an average exercise price of $2.10 per share, and we received $195,100 from the exercise of 335,000 common stock options, at an average exercise price of $0.58 per share.
At January 31, 2011, we had total liabilities of $1,173,900, an increase of $574,700 from July 31, 2010. Included in current liabilities is $322,100 of deferred revenue related to amounts billed for product shipped where payment on agreed terms was not reasonably assured at the time of shipment. Accounts payable and accrued liabilities also increased from July 31, 2010, by $268,700, due primarily to the timing of accounts payable and accrued salaries and wages.
Read the The complete Report
